MediPharm Labs Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Greg Hunter
- Full Time Employees
- 127
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 151 John Street Barrie ON Canada L4N 2L1
- IPO Date
- Feb 9, 2018
- Website
- medipharmlabs.com
- Similar Companies
- Business
- MediPharm Labs Corp. (TSX: LABS) specializes in the development, formulation, processing, packaging, and distribution of purified, pharmaceutical-grade cannabis concentrates, active pharmaceutical ingredients, and advanced cannabinoid-based derivative products utilizing Good Manufacturing Practices-certified facilities with ISO-standard cleanrooms. Founded in 2015 and headquartered at 151 John Street in Barrie, Ontario, Canada, the company operates primarily in the medical cannabis sector through wholesale, white-label, and branded platforms, serving domestic and international markets including Canada, Australia, Germany, and Brazil. Its core offerings encompass GMP cannabis API in bulk wholesale formats such as concentrates, distillates, and isolates across various cannabinoid ratios; white-label production of tinctures, soft gel capsules, vape cartridges, topicals, and custom formulations for applications in cosmetics, food and beverage, nutraceuticals, and over-the-counter or prescribed medications; and its proprietary MediPharm branded portfolio featuring high-potency oils like CBD25, CBD50, CBD100, THC30, CBN:THC 1:2, CBG:CBD 1:2, and balanced CBD:THC 20:20 in MCT or olive oil carriers, alongside soft chews, gel capsules, vape cartridges, inhalers, and dissolving drops with precise dosing in CBD, THC, CBN, and CBG profiles. The company supports clinical trials with drug-licensed materials and regulatory assistance, and maintains academic partnerships with institutions like McMaster University and Loyalist College for cannabis research. Recent developments include a landmark January 2025 commercial agreement with Brazil's Laboratório Teuto to supply full-spectrum GMP sublingual oral solutions into the $198 million medical cannabis market serving over 670,000 patients, with initial shipments pending ANVISA and Health Canada permits; the 2023 acquisition of VIVO Cannabis Inc., which expanded medical e-commerce access via Canna Farms in Canada and Beacon Medical operations in Australia and Germany while delivering revenue synergies and operating expense reductions from $40 million to half; and robust Q3 2025 financial performance with $11.4 million in revenue, up 17% year-over-year, driven by 83% growth in international medical cannabis sales.
Company News
MediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to Panama
MediPharm Labs Corp. (LABS:CA) Q2 2026 Earnings Call Transcript
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer's Disease and Dementia
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
MediPharm Labs Corp. (LABS:CA) Q1 2026 Earnings Call Transcript
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
MediPharm Labs Corp. (LABS:CA) Q4 2025 Earnings Call Transcript
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns